anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To regulate lymphocyte effectively by cross conjugating at least two molecules conjugable with an antigen on lymphocyte such that each molecule exhibits reactivity to a different antigen on each lymphocyte. CONSTITUTION: A heteroconjugate comprising at least two cross conjugated antibodies each exhibiting reactivity to a different antigen on the surface of lymphocyte is employed. These heteroconjugates are conjugated with a lymphocyte and act to bring respective cell surface antigens on which they react close to each other physically thus enhancing introduction of character or proliferation of lymphocyte or generating a reduction signal. In a preferred embodiment, an antibody reactive to T cell receptor or CD3 complex thereof is cross conjugated with an antibody reactive to second T cell surface antigen, e.g. CD2, CD4, CD6 or CD8, in order to accelerate activation and function of second T cell. Consequently, cellular immunological reaction can effectively be improved by regulating the lymphocyte.
Krüppel-like factor 13 (KLF13), a zinc finger transcription factor, is considered as a potential regulator of cardiomyocyte differentiation and proliferation during heart morphogenesis. However, its precise role in the dedifferentiation of vascular smooth muscle cells (VSMCs) during atherosclerosis and neointimal formation after injury remains poorly understood. In this study, we investigated the relationship between KLF13 and SM22α expression in normal and atherosclerotic plaques by bioanalysis, and observed a significant increase in KLF13 levels in the atherosclerotic plaques of both human patients and ApoE-/- mice. Knockdown of KLF13 was found to ameliorate intimal hyperplasia following carotid artery injury. Furthermore, we discovered that KLF13 directly binds to the SM22α promoter, leading to the phenotypic dedifferentiation of VSMCs. Remarkably, we observed a significant inhibition of platelet-derived growth factor BB-induced VSMCs dedifferentiation, proliferation, and migration when knocked down KLF13 in VSMCs. This inhibitory effect of KLF13 knockdown on VCMC function was, at least in part, mediated by the inactivation of p-AKT signaling in VSMCs. Overall, our findings shed light on a potential therapeutic target for treating atherosclerotic lesions and restenosis after vascular injury.
After screening, patients will undergo a combination therapy of OBP-301 with radiation therapy for 6 weeks. At Day 1, Day 18 and Day 32, OBP-301 is directly injected to the location of the lesion. From Day 4, patients receive radiation therapy. Patients will be automatically entered follow-up period for 12 weeks to be observed tolerance and safety.

This study is designated as standard 3 + 3 dose escalation study. The first 3 patients will be evaluated with low-dose of OBP-301 and then the study move onto the high-dose cohort of OBP-301. When the DLT (Dose Limiting Toxicity) is observed, 3 more patients will be enrolled in the dose level.
Data from a Phase 3 study of Prograf in conjunction with azathioprine indicate that trough concentrations of tacrolimus in whole blood, as measured by IMx® were most variable during the first week of dosing. During the first three months of that trial, 80% of the patients maintained trough concentrations between 7-20 ng/mL, and then between 5-15 ng/mL, through 1 year.

In a separate clinical trial of Prograf in conjunction with MMF and daclizumab, approximately 80% of patients maintained tacrolimus whole blood concentrations between 4-11 ng/mL through 1 year post-transplant. 

In another clinical trial of Prograf in conjunction with MMF and basiliximab, approximately 80% of patients maintained tacrolimus whole trough blood concentrations between 6-16 ng/mL during month 1-3 and, then, between 5-12 ng/mL from month 4 through 1 year.

The relative risks of toxicity and efficacy failure are related to tacrolimus whole blood trough concentrations. Therefore, monitoring of whole blood trough concentrations is recommended to assist in the clinical evaluation of toxicity and efficacy failure.
TQB2450 injection, 21 days as a treatment cycle. AL2846 capsule, 21 days as a treatment cycle. Pemetrexed disodium for injection, 21 days as a treatment cycle. Cisplatin injection, 21 days as a treatment cycle.
PROBLEM TO BE SOLVED: To provide a device made up of a specific implant constructed for e.g. the subcutaneous administration of an androgen and a 2nd specific implant constructed for e.g. the subcutaneous administration of a spermatocide so as to be useful for male contraception or the like. SOLUTION: This device is made up a 1st implant 10 composed of such a quantity of an androgen 15 (pref. MENT) as to be enough to offer its daily dose as the effective quantity (pref. about 200-500 μg) over a specified time period (pref. about 180 days or longer) dispersed in a core 11 made of silicone elastomer and a membrane 17 made of ethylene-vinyl acetate copolymer and enveloping the above core, and designed to ensure the subcutaneous or local administration of the androgen, and a 2nd implant containing such a quantity of a spermatocide as to be enough to offer its daily dose as the effective quantity over the above-mentioned time period and designed to ensure the subcutaneous or local administration of the spermatocide.
Method of building resistance to Covid-19 disease development. The strong link between the distribution of Covid-19 disease (CV) severity across the United States population and that of systemic inflammation, as indicated in the individual's C-reactive protein (CRP) level, explains the widely varied symptomatic responses of individuals afflicted with the virus. The data are consistent with the fewer infections and deaths reported for the Asian countries. The disease pathologies of CV and non-specific interstitial pneumonia (NSIP) patients bear close similarities. Modeling the disease as a chemically reactive process indicates that the virus catalyzes the inflammation driven reaction, causing lung infiltration and injury, up to and including patient death. Prevention methods involving exercise and diet successfully applied for lung stabilization in NSIP also apply to CV mitigation, the goal of which is to achieve pre-disease CRP levels of <10 mg/L, and preferably <3 mg/L, and more preferably <1 mg/L.
Classes assigned to this condition received the mindfulness-based intervention. The MBI program implemented comprised ten weekly sessions. Activities were drawn from the Mission Méditation program, a MBI intervention specifically tailored for elementary school children. Activities comprised in this intervention encompassed formal (e.g., body scan, sitting, and breathing meditation) and informal meditations (e.g., mindful eating, listening, and touching, mindful walking), as well as positive psychology exercises (e.g., taking care of oneself, gratitude). The weekly sessions, lasting 45 to 60 minutes each, were delivered in a group format by the teachers themselves, in their classroom.
This will be a double-blind, three-way crossover study comparing combination vilanterol+fluticasone with fluticasone monotherapy and a placebo (vilanterol is not available as a monotherapy). The order in which the treatments are given will be randomized and each treatment will be separated by a minimum one-week washout. Fifteen asthmatic participants will be recruited from the local community. Methacholine challenge testing (MCT) with the two-minute tidal breathing protocol will be used to quantify the bronchoprotective effects (if any) of each treatment against methacholine-induced bronchoconstriction.

Each participant will undergo a total of nine methacholine challenges. After a baseline methacholine challenge, the randomized treatment (identity unknown to investigator or participant) will be administered through an Ellipta® (multi-dose dry powder inhaler). Thirty minutes following treatment administration, a second methacholine challenge will be performed. At 24 hours post-treatment, each participant must re-visit the lab for one methacholine challenge. The same process will be followed for each treatment.
PURPOSE:To provide an emulsified hair cosmetic for after-shampooing, giving soft feeling in rinsing and springy and bulky feeling to the hair after drying, having high safety and exhibiting excellent emulsion stability over a wide pH range. CONSTITUTION:The objective hair cosmetic contains (A) 0.5-10wt.% of an amphoteric surfactant, preferably an amidoamino acid-type surfactant (e.g. amidoamino acid triethanolamine salt) or imidazoline-type surfactant (e.g. 2-lauryl-N- carboxymethyl-Nhydroxyethylimidalium betaine), (B) 0.01-2wt.% of a cationized polymer, e.g. cationized cellulose drrivative, cationic startch or polydimehtylmethylene piperdinium chloride, (C) 1.0-50wt.% of an oil such as silicone oil or higher alcohol and (D) 0.5-10wt.% of an inorganic salt such as sodium chloride or magnesium sulfate. The cosmetic is applied to hair after shampooing and washed off from the hair.
Randomized at daily time point to receive a drinking-focused message. Randomization probability for this arm is .40.
OBJECTIVE: To investigate the expression of Nanog and its regulatory relationship with MMP-2/MMP-9 proteins in esophageal squamous cell carcinoma (ESCC).
METHODS: We detected Nanog and MMP-2/MMP-9 protein expressions in 127 ESCC tissues and 82 adjacent normal tissues using immunohistochemistry and explored their correlations with the clinicopathological parameters and prognosis of the patients. GEO database was utilized to analyze the pathways enriched with the stemness-related molecules including Nanog, and TIMER online tool was used to analyze the correlations among TβR1, MMP-2, and MMP-9 in esophageal cancer.
RESULTS: Nanog and MMP-2/MMP-9 proteins were significantly upregulated in ESCC tissues and positively intercorrelated. Their expression levels were closely correlated with infiltration depth and lymph node metastasis of ESCC but not with age, gender, or tumor differentiation. The patients with high expressions of Nanog and MMP-2/MMP-9 had significantly shorter survival time. Bioinformatics analysis showed enrichment of stemness-associated molecules in the TGF-β signaling pathway, and the expressions of MMP-2/MMP-9 and TβR1 were positively correlated. In cultured ESCC cells, Nanog knockdown significantly decreased the expression of TβR1, p-Smad2/3, MMP-2, and MMP-9 and strongly inhibited cell migration.
CONCLUSION: The high expressions of Nanog, MMP-2, and MMP-9, which are positively correlated, are closely related with invasion depth, lymph node metastasis, and prognosis of ESCC. Nanog regulates the expressions of MMP-2/MMP-9 proteins through the TGF-β signaling pathway, and its high expression promotes migration of ESCC cells.
Fosamax Tablets 70 mg of Merck \& Company. Inc., USA.
INTRODUCTION: People's understanding of bladder stones has a long history. Since around the sixth century BC, surgery has been selected as the most specialized and last treatment and has continuously evolved. Meanwhile, many missing links have sometimes been a turning point in bladder stone surgery. The efforts of Iranian medicine scholars in advancing this treatment method are part of the impressive ups and downs of this path, which is discussed in this research.
METHODS: This review research is based on Persian medicine sources, such as Al-Hawi fi al-Tabb, The Kitāb al-Taṣrīf, and Al-Qanun fi al-Tebb. It has also used reliable databases such as Pub Med, Scopus, and Elsevier, as well as search engines such as Google Scholar, with related keywords.
RESULTS: Surgery as the last treatment method for bladder stones was first proposed in the Golden Age (800-1300AD) of Persian traditional medicine by Ali ibn Rabben Tabari (810-895 AD) and Rhazes (865-925 AD), who discussed it in more detail. Then Hally Abbas, Albucasis, and Avicenna completed and enriched it. Albucasis's role is imposing due to his unique techniques in perineal cystolithotomy, forceps to extract bladder stones, and primary lithotrity until the nineteenth century.
CONCLUSION: Examining the evolution and progress of bladder stone treatment shows the efforts of physicians in different medical schools. The brilliance of the sages of Persian Medicine, who invented seven different types of bladder stone surgery, improved the techniques of the predecessors and created a significant leap in the progress of this surgery.
BACKGROUND: There is a growing demand for advanced methods to improve the understanding and prediction of illnesses. This study focuses on Sepsis, a critical response to infection, aiming to enhance early detection and mortality prediction for Sepsis-3 patients to improve hospital resource allocation.
METHODS: In this study, we developed a Machine Learning (ML) framework to predict the 30-day mortality rate of ICU patients with Sepsis-3 using the MIMIC-III database. Advanced big data extraction tools like Snowflake were used to identify eligible patients. Decision tree models and Entropy Analyses helped refine feature selection, resulting in 30 relevant features curated with clinical experts. We employed the Light Gradient Boosting Machine (LightGBM) model for its efficiency and predictive power.
RESULTS: The study comprised a cohort of 9118 Sepsis-3 patients. Our preprocessing techniques significantly improved both the AUC and accuracy metrics. The LightGBM model achieved an impressive AUC of 0.983 (95% CI: [0.980-0.990]), an accuracy of 0.966, and an F1-score of 0.910. Notably, LightGBM showed a substantial 6% improvement over our best baseline model and a 14% enhancement over the best existing literature. These advancements are attributed to (I) the inclusion of the novel and pivotal feature Hospital Length of Stay (HOSP_LOS), absent in previous studies, and (II) LightGBM's gradient boosting architecture, enabling robust predictions with high-dimensional data while maintaining computational efficiency, as demonstrated by its learning curve.
CONCLUSIONS: Our preprocessing methodology reduced the number of relevant features and identified a crucial feature overlooked in previous studies. The proposed model demonstrated high predictive power and generalization capability, highlighting the potential of ML in ICU settings. This model can streamline ICU resource allocation and provide tailored interventions for Sepsis-3 patients.
Vulnerable children, including those with neuro-developmental delays and disabilities, often face barriers in accessing early primary education, thus hindering progress toward Sustainable Development Goal 4.2. Evidence-based interventions are essential to enhancing inclusivity and establishing sustainable implementation strategies to address this challenge. This study, Every Newborn - Reach up Early Education Intervention for All Children (EN-REACH), builds on the previous Every Newborn- Simplified Measurement Integrating Longitudinal Neurodevelopmental and Growth (EN-SMILING) observational cohort study. This is a cluster randomized controlled trial (cRCT) to evaluate the effectiveness of a parenting group intervention program for enhancing school readiness in Bangladesh, Nepal, and Tanzania, and an embedded process evaluation to inform scalability and feasibility.

EN-REACH is a cRCT with 150 clusters to evaluate the impact of a parent training program led by trained parent-teacher facilitator pairs, focusing on children aged 4\~6 years preparing for preschool. Approximately 500 participants from the EN-SMILING cohort at each site have been identified. A geographic information system will define \~50 clusters in each of the three countries, each with approximately ten parent-child dyads. Half the clusters will be randomly assigned to intervention and control groups. The primary outcome is "school readiness", assessed using the Measuring Early Learning Quality and Outcomes (MELQO) tool. Secondary outcomes include Intelligence Quotient, child functioning, growth, visual, and hearing assessments. Data will be collected at baseline, and post-intervention data following implementation of the parent group intervention sessions over approximately 5-months. Quantitative data on coverage and quality care, combined with qualitative insights from children, caregivers, facilitators, and stakeholders' perspectives, will be used to conduct a process evaluation applying the RE-AIM framework.

This trial focused on enhancing school readiness and cognitive abilities in young children, inclusive of those with disabilities, aims to bridge gap from home to early primary education. EN-REACH aims to provide insights into the effectiveness and acceptability of a co-designed disability-inclusive school readiness program in three countries, potentially impacting national, and global policies for all children, including those with disabilities.
Compounds and methods suppressing aromatase activity expression in cancer cells. Provided are compounds are those of formula I: wherein R1 may be alkyl, cycloakyl, haloalkyl, aryl, substituted aryl, haloaryl, alkoxy, alkylaryl, and arylalkyl; R2 is H, alkyl, aryl, alkylaryl, arylalkyl, and cycloalkyl; R3, with the base nitrogen, forms an amide or sulfonamide; R4 is selected from nitro, amine, amide, and benzamide; or a pharmaceutically acceptable salts thereof. Also provided are small molecule selective aromatase inhibitors having a molecular weight of less 500 g/mol. In some embodiments, the small molecule selective aromatase inhibitors described herein have a molecular weight of less than 450 g/mol. Also provided are methods for suppressing aromatase activity expression in cancer cells comprising the step of administering a pharmaceutically effective amount of a small molecule aromatase inhibitor to a subject in need of such treatment. In one embodiment, the cancer cells are breast cancer cells.
Computer-implemented methods and systems for managing the collection of and access to behavior assessment data. In an embodiment, a first user having authority to act on behalf of an individual under study identifies a second and third user role, specifies behavior data, symptom measurement data, and/or medicine regimen data associated with the individual under study, and defines access permissions for the second and third user roles with respect to the behavior data and symptom measurement data. The symptoms and behaviors to be measured are specified based on a condition of the individual. Users provide behavior data and symptom measurement data observed from the individual. An analytics module performs computational analysis on the behavior data and symptom measurement data, thereby producing behavior assessment data. A reporting module presents the behavior assessment data to the users in a manner consistent with the defined access permissions.
The invention relates, inter alia, to the use of neuregulin-β as a target in a screening method for active compounds, in particular for exerting an influence on changes in calcium concentration which are mediated by glutamate receptors. The invention furthermore relates to the use of neuregulins, preferably a neuregulin isoform having an isoelectric point in the range from pH 4.3 to 5.0, as a target for detecting and/or exerting an influence on neuronal processes, in particular for exerting an influence on long-term memory. Neuregulins, in particular neuregulin-.beta. and also substances which exert an influence on the status, i.e. the expression and/or post -translational modification, of neuregulin-.beta., can therefore be used as agents for controlling the course of, treating and/or alleviating neuronal diseases, e.g. Alzheimer's disease.
Compositions and methods for enhancing an immune response and treating cancer are provided. Compositions comprise PD-1 axis antagonists and HPK1 antagonists. PD-1 axis antagonists include PD-1 antagonists, PD-L1 antagonists, and PD-L2 antagonists. PD-1 axis antagonists can inhibit the binding of PD-L1 and/or PD-L2 to PD-1. HPK1 antagonists include compounds that inhibit the serine/threonine kinase activity of HPK1. Methods for enhancing an immune response or treating cancer comprise administering a PD-1 axis antagonist and a HPK1 antagonist, sequentially or simultaneously, to a subject in need thereof.
PURPOSE:To obtain a hair tonic, containing elaidic acid and/or linoelaidic acid, having excellent hair tonic effects and further extremely effective in preventing dandruff and pruritus. CONSTITUTION:A hair tonic containing one or two or more ingredients selected from the group consisting of elaidic acid and linoelaidic acid. The above- mentioned compounds which are active ingredients can be used not only in the form of free acids but also as derivatives in the form of salts, such as sodium salt, or esters with an alkyl group, such as propyl. All thereof will not exhibit toxicity to human bodies. The blended amount is not especially limited; however, the content is preferably normally 0.01-10wt.% without exhibiting toxicity to human bodies. The elaidic acid and linoelaidic acid may be used alone or together and further in combination with conventional hair tonic drug effective agents.
BACKGROUND: Bradycardia and dysautonomia observed during SARS-Cov2 infection suggests involvement of the autonomic nervous system (ANS). Limited data exists on ANS dysregulation and its association with outcomes in patients with acute respiratory distress syndrome (ARDS) related to COVID-19 (C-ARDS) or other etiologies (NC-ARDS).
OBJECTIVES: We aimed to explore sympathovagal balance, assessed by heart rate variability (HRV), and its clinical prognostic value in C-ARDS compared with NC-ARDS.
METHODS: A single-center, prospective case-control study was conducted. Consecutive patients meeting ARDS criteria between 2020 and 2022 were included. HRV was assessed using 1-hour electrographic tracing during a stable, daytime period.
RESULTS: Twenty-four patients with C-ARDS and 19 with NC-ARDS were included. Age, sex and ARDS severity were similar between groups. The median heart rate was markedly lower in the C-ARDS group than in the NC-ARDS group (60 [53-72] versus 101 [91-112] bpm, p<.001). Most of HRV parameters were significantly increased in patients with C-ARDS. HRV correlated with heart rate only in patients with C-ARDS. A positive correlation was found between the low-to high-frequency ratio (LF/HF) and length of intensive care unit stay (r = 0.576, p<.001).
CONCLUSION: This study confirmed that C-ARDS was associated with marked bradycardia and severe ANS impairment, suggesting a sympathovagal imbalance with vagal overtone. Poor outcomes appeared to be more related to sympathetic rather than parasympathetic hyperactivation.
PURPOSE:To rapidly obtain the dental porcelain frame for prosthetic restoration of the front tooth part having excellent strength and toughness by forming the dental porcelain frame of a material formed by impregnating a ceramic porous layer contg. metal with glass. CONSTITUTION:This dental porcelain frame consists of the material formed by impregnating the ceramic porous layer contg. the metal with the glass. Gold (Au) is adequately used as the metal and alumina (Al2O3) as the ceramics Glass having constituting components consisting of B2O3, SiO2, Al2O3 and La2O3 is used as the glass and is so formed that the compsn. ratios (molar ratios) thereof are (SiO2+Al2O3)/(SiO2+Al2O3+B2O3+La2O3)=0.40 to 0.52 and B2O3/(B2O3+La2 O3)=0.46 to 0.72. As a result, the dental porcelain frame having the excellent strength and toughness is obtd. in an extremely short period of time.
FIELD: stomatology, in particular, stomatological materials promoting osteogenesis of osseous tissue during various pathogenic processes. SUBSTANCE: material comprises powdery or granular hydroxyl apatite and tricalcium phosphate in ratio of 3-4:1, lincomicyn, trypsine and directly acting anticoagulants. These components are taken in proper weight ratio. Material has paste-like consistency. EFFECT: suppression of inflammatory process during postoperative period. 2 dwg